Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 5, 2002, Pages 678-681

  Kowari, Kouji ^a   Hirosawa, Iori ^a   Kurai, Hirono ^a   Utoguchi, Naoki ^a   Fujii, Makiko ^a   Watanabe, Yoshiteru ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

cyclodextrin; Hollow type suppository; Human chorionic gonadotropin; Plasma human chorionic gonadotropin concentration; Plasma testosterone concentration; Rectal administration

Indexed keywords

ALPHA CYCLODEXTRIN; CHORIONIC GONADOTROPIN; TESTOSTERONE; WITEPSOL; ALPHA CYCLODEXTRIN DERIVATIVE; ALPHA-CYCLODEXTRIN; CYCLODEXTRIN;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; EXPERIMENTAL MODEL; NONHUMAN; PHARMACODYNAMICS; RABBIT; SUPPOSITORY; TESTOSTERONE BLOOD LEVEL; ANIMAL; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, RECTAL; ALPHA-CYCLODEXTRINS; ANIMALS; AREA UNDER CURVE; CHORIONIC GONADOTROPIN; CYCLODEXTRINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RABBITS; SUPPOSITORIES; TESTOSTERONE;

EID: 0036583920     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.678     Document Type: Article

References (22)

1. This paper is part XXIII of "Pharmaceutical Evaluation of Hollow-Type Suppositories," Part XXII: Watanabe Y., Mizufune Y., Kuboyama A., Kiriyama M., Utoguchi N., Matsumoto M., Biol. Pharm. Bull., 19, 1187-1190 (1998).
2. This study was presented, in part, at the Millennial World Congress of Pharmaceutical Sciences held in San Francisco, U.S.A., April, 2000.
3. Morgan F. J., Canfeld R. E., J. Biol. Chem., 250, 5247-5258 (1975).
4. The United States Pharmacopeial Convention, Inc. (ed.), "USP DI, 21st ed.," Rand McNally, Taunton, MA, U.S.A., 2001, pp. 872-875.
5. "USP24-NF19," The United States Pharmacopeial Convention, Inc., Rockville, MD, U.S.A., 2000, pp. 786-787.
6. Watanabe Y., Matsumoto Y., Baba K., Matsumoto M., J. Pharmacobio-Dyn.,9, 526-531 (1986).
7. Watanabe Y., Matsumoto Y., Hori N., Funato H., Matsumoto M., Chem. Pharm. Bull., 39, 3007-3012 (1991).
8. Watanabe Y., Kiriyama M., Ito R., Kikuchi R., Mizufune Y., Nomura H., Miyazaki M., Matsumoto M., Biol. Pharm. Bull., 19, 1059-1063 (1996).
9. Watanabe Y., Kiriyama M., Oe J., Kikuchi R., Mizufune Y., Matsumoto M., Biol. Pharm. Bull., 19, 1064-1067 (1996).
10. Watanabe Y., Matsumoto Y., Seki M., Takase M., Matsumoto M., Chem. Pharm. Bull., 40, 3042-3047 (1992).
11. Suzuki N., Konishi E., Kondo K., Fujita I., Ishikawa E., Clinica Chimica Acta, 150, 247-253 (1985).
12. Sato Y., Suda Y., Hirohashi T., Takeuchi S., Acta Obst. Gynaec. Jpn., 38, 1079-1086 (1986).
13. Maxey K. M., Maddipati K. R., Birkmeier J., J. Clin Immunoassay, 15, 116-120 (1992).
14. Ritschel W. A., "Handbook of Basic Pharmacokinetics," 2nd ed., Drug Intelligence Publication, Hamilton, IN, U.S.A., 1980, pp. 274-283.
15. Watanabe Y., Matsumoto Y., Kawamoto K., Yazawa S., Matsumoto M., Chem. Pharm. Bull., 40, 3100-3104 (1992).
16. Irie T., Wakamatsu K., Arima H., Aritomi H., Uekama K., Int. J. Pharmaceut., 84, 129-139 (1992).
17. Lee V. H. L., J. Controlled Rel., 13, 213-223 (1990).
18. Shibuya M., Irie T., Uekama K., Minutes of the 5th International Symposium on Cyclodextrins, Paris, 1990, pp. 483-486.
19. Uekama K., Otagiri M., CRC Crit. Rev. Ther. Drug Car. Syst., 3, 140 (1987).
20. Arima H., Wakamatsu K., Aritomi H., Irie T., Uekama K., Minutes of the 5th International Symposium on Cyclodextrins, Paris, 1990, pp. 487-490.
21. Veijola M., Kellokumpu S., Hormone Res., 19, 191-199 (1984).
22. Hodgson Y. M., deKretser D. M., Int. J. Androl., 5, 81-91 (1982).